Intest Res > Volume 18(4); 2020 > Article |
|
FINANCIAL SUPPORT
The study was conducted with the financial support of the EGIS Pharmaceuticals PLC Representative office in Kazakhstan and Takeda Pharmaceutical Company Limited.
AUTHOR CONTRIBUTION
Study design: Kaibullayeva J, Ualiyeva A, Oshibayeva A. Data collection: Kaibullayeva J, Ualiyeva A, Oshibayeva A, Dushpanova A. Data analysis: Kaibullayeva J, Ualiyeva A, Oshibayeva A. Discussion of results: Kaibullayeva J, Ualiyeva A, Oshibayeva A, Marshall JK. Writing the manuscript: all authors. Approval of final manuscript: all authors.
Characteristics | Unaware (n=25) | Aware (n=103) | P-valuea |
---|---|---|---|
Sex | 0.121 | ||
Male | 7 (28) | 47 (45.6) | |
Female | 18 (72) | 56 (54.4) | |
Age (yr) | 0.187 | ||
18-40 (A2) | 16 (64) | 50 (48.5) | |
> 40 (A3) | 9 (36) | 53 (51.5) | |
Area | 0.943 | ||
Urban | 19 (76) | 75 (72.8) | |
Rural | 6 (24) | 28 (27.2) |
Characteristics | Unaware (n=25) | Aware (n=103) | P-value |
---|---|---|---|
IBD type | 0.332a | ||
UC | 16 (64) | 76 (73.8) | |
CD | 9 (36) | 27 (26.2) | |
Stool frequency, time/day | < 0.001 | ||
<5 | 23 (92) | 49 (47.6) | |
6-10 | 2 (8) | 37 (35.9) | |
> 10 | 0 (0) | 17 (16.5) | |
Requires steroids treatment (yes) | 9 (37.5) | 42 (48.3) | 0.367a |
History of GIT surgery due to IBD (yes) | 2 (8) | 12 (11.7) | 0.867b |
Blood in stool (yes) | 7 (28) | 26 (25.2) | 0.801a |
Abdominal pain (yes) | 8 (32) | 19 (18.4) | 0.171a |
Subfebrile fever (yes) | 10 (40) | 33 (32.0) | 0.487a |
Perianal disease (yes) | 2 (8) | 22 (21.4) | 0.159b |
Aphthae (yes) | 5 (20) | 23 (22.3) | 1.000a |
Abdominal infiltrate (yes) | 3 (12) | 8 (7.8) | 0.448b |
Skin disorders (yes) | 4 (16) | 8 (7.8) | 0.248b |
Musculoskeletal disorders (yes) | 11 (44) | 58 (56.3) | 0.371a |
Hepatobiliary system disorders (yes) | 2 (8) | 33 (32.0) | 0.022b |
BMI (kg/m2) | 0.243a | ||
< 18.5 | 2 (8) | 11 (10.7) | |
18.5-24.99 | 16 (64) | 68 (66.0) | |
25-30 | 7 (28) | 18 (17.5) | |
>30 | 0 | 6 (5.8) |